FSTL3 expression also was associated with reduced OS (p = 0.0005, HR = 2.198 [1.411–3.424]) (Figure 2A), DSS (p = 0.0003, HR = 3.027 [1.6545–5.537]) (Figure 2C) and progression‐free interval (PFI) (p = 0.0025, HR = 1.877 [1.248–2.823]) (Figure 2D) in patients with CRC. This evidence concerns the gene FSTL3 and colorectal carcinoma.